Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Kinnate Biopharma Inc
(NQ:
KNTE
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
2.650 (47)
Ask (Size)
2.670 (37)
Prev. Close
2.650
Today's Range
N/A - N/A
52wk Range
1.040 - 2.690
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
XOMA Corporation Announces Closing of Tender Offer
April 03, 2024
Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right
From
XOMA Corporation
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
March 25, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Performance
More News
Read More
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
March 19, 2024
From
XOMA Corporation
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –
March 19, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
March 13, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB)
March 13, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
March 01, 2024
From
Kinnate Biopharma; Pierre Fabre Laboratories
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB)
February 26, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB)
February 20, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
February 19, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
February 16, 2024
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB)
February 16, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders
February 16, 2024
From
NEW YORK
Via
Business Wire
Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share
February 16, 2024
From
Kinnate Biopharma
Via
GlobeNewswire
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
February 16, 2024
From
XOMA Corporation
Via
GlobeNewswire
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 15, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 15, 2023
Via
Benzinga
Kinnate Biopharma Inc. (NASDAQ: KNTE) is One of Wednesday Morning’s Most Active Stocks
November 15, 2023
Via
Investor Brand Network
Why is Cancer-Focused Kinnate Biopharma Stock Trading Higher Today?
November 15, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 15, 2023
Via
Benzinga
Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
November 09, 2023
From
Kinnate Biopharma
Via
GlobeNewswire
Analysts Move To Sidelines For Cancer Player Kinnate Biopharma After Restructuring
September 19, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
September 19, 2023
Via
Benzinga
Why Is Cancer Firm Kinnate Biopharma Stock Trading Lower Today?
September 19, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 19, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.